Nav: Home

Genetic biomarker linked to improved survival for patients with certain brain tumors

June 28, 2018

A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

New data reported in the June 28, 2018, issue of the medical journal JAMA Oncology shows that patients with MGMT methylated tumors are more than twice as likely to survive after combination temozolomide and radiation treatment than patients with unmethylated tumors.

Gliomas are a class of brain tumors that develop in the supportive cells that surround nerve cells in the brain.

Study Methods and Results

Previously reported findings from the NRG Oncology/RTOG 0424 clinical trial report a three-year overall survival benefit for certain brain tumor patients who receive the drug temozolomide in addition to radiation therapy compared with the standard of care. Data regarding the significance of MGMT promoter methylation status, however, was not examined.

This new study represents the first published data showing that MGMT promoter methylation status can be used to predict patient outcomes.

Researchers conducted a retrospective analysis of 129 glioma patients who participated in the NRG Oncology/RTOG 0424 clinical trial. Of these patients, 75 patients had tissue samples available that could be analyzed for MGMT promoter methylation status.

Using various statistical methods, researchers confirmed that MGMT promoter methylation can be used as an independent prognostic biomarker of high-risk, low-grade glioma in patients treated with temozolomide and radiotherapy.

"Identifying biomarkers - prognostic and predictive markers - is critical for personalizing care and giving patients the best quality of life and chances of longer survival," says Arnab Chakravarti, MD, senior author of the study and chair of radiation oncology at the OSUCCC - James. "These tumors are tricky to treat because there is such a wide range of outcomes. Some patients succumb to the disease within months, others live years beyond their diagnosis. We need better methods of determining which patients are likely to have more aggressive tumors."

This new data represents the first clinical trial-based evidence of the prognostic importance of MGMT promoter methylation in patients with grade II glioma. Previously published data on MGMT promoter methylation as a biomarker of survival outcomes is related to the malignant brain tumor, glioblastoma.

"This is also the first data to highlight the test's potential prognostic value beyond a standard molecular test currently used (IDH1/2 mutation status) to help predict patient survival outcomes," adds Erica Bell, PhD, first author of the study and scientist with the OSUCCC - James Translational Therapeutics Research Program.
-end-
This research was supported by grants from NRG Oncology, the National Cancer Institute, The OSUCCC - James, Merck and Pennsylvania Department of Health. Authors have no financial interests in the study sponsor, Merck.

Collaborators come from the OSUCCC - James, NRG Oncology, London Regional Cancer Program, Wake Forest University, Toronto General Hospital/Princess Margaret, St. Joseph's Hospital and Medical Center-Accruals Arizona Oncology Services Foundation, Thomas Jefferson University Hospital, Henry Ford Hospital, Hospitalier de L ' Universite de Montreal-Notre Dame,University of Maryland Medical Systems, H. Lee Moffit Cancer & Research Institute, Mayo Clinic, University of Washington Medical Center-Accruals, University of California-San Francisco, University of Wisconsin Hospital-Madison, and Baptist Hopsital of Miami and include: Peixin Zhang, PHD, Barbara Fisher, MD, David Macdonald, MD, Joseph McElroy, PhD, Glenn Lesser, MD, Jessica Fleming, MD, Arup Chakraborty, PhD, Ziyann Liu, Aline Becker, MD, PhD, Denise Fabian, MD, Kenneth Aldape, MD, Lynn Ashby, MD, Maria Werner-Wasik, MD, Eleanor Walker, MD, Jean-Paul Bahary, MD, Young Kwok, MD, Michael Yu, MD, Nadia Laack, MD, Christopher Schultz, MD, Heidi Gray, MD, Ian Robins, MD, PhD, and Minesh Mehta, MD.

The Ohio State University Comprehensive Cancer Center

Related Brain Articles:

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.
Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.
BRAIN Initiative tool may transform how scientists study brain structure and function
Researchers have developed a high-tech support system that can keep a large mammalian brain from rapidly decomposing in the hours after death, enabling study of certain molecular and cellular functions.
Wiring diagram of the brain provides a clearer picture of brain scan data
In a study published today in the journal BRAIN, neuroscientists led by Michael D.
Blue Brain Project releases first-ever digital 3D brain cell atlas
The Blue Brain Cell Atlas is like ''going from hand-drawn maps to Google Earth'' -- providing previously unavailable information on major cell types, numbers and positions in all 737 brain regions.
Landmark study reveals no benefit to costly and risky brain cooling after brain injury
A landmark study, led by Monash University researchers, has definitively found that the practice of cooling the body and brain in patients who have recently received a severe traumatic brain injury, has no impact on the patient's long-term outcome.
Brain cells called astrocytes have unexpected role in brain 'plasticity'
Researchers from the Salk Institute have shown that astrocytes -- long-overlooked supportive cells in the brain -- help to enable the brain's plasticity, a new role for astrocytes that was not previously known.
Largest brain study of 62,454 scans identifies drivers of brain aging
In the largest known brain imaging study, scientists from Amen Clinics (Costa Mesa, CA), Google, John's Hopkins University, University of California, Los Angeles and the University of California, San Francisco evaluated 62,454 brain SPECT (single photon emission computed tomography) scans of more than 30,000 individuals from 9 months old to 105 years of age to investigate factors that accelerate brain aging.
Is whole-brain radiation still best for brain metastases from small-cell lung cancer?
University of Colorado Cancer Center study compares outcomes of 5,752 small-cell lung cancer patients who received whole-brain radiation therapy (WBRT) with those of 200 patients who received stereotactic radiosurgery (SRS), finding that the median overall survival was actually longer with SRS (10.8 months with SRS versus 7.1 months with WBRT).
Atlas of brain blood vessels provides fresh clues to brain diseases
Even though diseases of the brain vasculature are some of the most common causes of death in the West, knowledge of these blood vessels is limited.
More Brain News and Brain Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.